Dr. Hanker received her B.Sc. in chemistry from the University of Virginia in 2004 and Ph.D. in genetics and molecular biology from the University of North Carolina at Chapel Hill in 2009. Her graduate work in the laboratory of Dr. Channing Der focused on strategies to disrupt membrane binding of the small GTPase Rheb, in an effort to block aberrant Rheb/mTOR signaling in cancer. Dr. Hanker pursued postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University Medical Center. During this time, she was awarded a postdoctoral fellowship from the Department of Defense Breast Cancer Research Program and a career development award (K12 award) from the National Cancer Institute. Her postdoctoral studies used transgenic mouse models and human breast cancer xenografts to study mechanisms of resistance to HER2-targeted therapy in HER2+ breast cancer.
More recently, Dr. Hanker identified the HER2 T798I gatekeeper mutation as a mechanism of resistance to HER2-targeted therapy in HER2-mutant breast cancer. Her current work focuses on understanding and targeting activating HER2 mutations found in breast and other cancers.
Dr. Hanker joined the faculty of UT Southwestern Medical Center in 2018. Her research program is supported by grants from the National Cancer Institute.
- University of Virginia-Ofc Fin (2004), Chemistry
- Graduate School
- University of N C-Chapel Hill (2009)
- breast cancer targeted therapy
- cancer biology
- cancer genomics
- drug resistance
- precision oncology
- receptor tyrosine kinases
- signal transduction
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.
- Hanker AB, Kaklamani V, Arteaga CL Cancer Discov 2019 Mar
- Genomic alterations of ERBB receptors in cancer: clinical implications.
- Mishra R, Hanker AB, Garrett JT Oncotarget 2017 Dec 8 69 114371-114392
- Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.
- Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL Cancer Res. 2017 Jun 77 12 3280-3292
- An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
- Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL Cancer Discov 2017 06 7 6 575-585
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
- Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL Nat Commun 2019 Mar 10 1 1373
- HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
- Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL Clin. Cancer Res. 2017 Aug 23 15 4323-4334
- Matching novel breast cancer mutations with potential therapies
- Hanker, AB Oncology Times 2017 39 22 36-37
- Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.
- Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z Breast Cancer Res. Treat. 2016 12 160 3 457-474
- Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
- Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, Yankeelov TE Breast Cancer Res. Treat. 2016 Jan 155 2 273-84
- In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
- Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K Nat. Genet. 2015 Oct 47 10 1212-9
The Roles of Ras Family Small GTPases in Breast Cancer. In Handbook of Cell Signaling 2ed
Hanker AB, Der CJ (2009). Cambridge, MA, Academic Press
Role of R-Ras in Cell Growth. In Handbook of Cell Signaling 2ed
Repasky GA, Cox AD, Hanker AB, Mitin N, Der CJ (2009). Cambridge, MA, Academic Press
Honors & Awards
- NIH/NCI SPORE in Breast Cancer Career Enhancement Award
- AACR-Susan G. Komen Scholar-in-Training Award, San Antonio Breast Cancer Symposium
- Vanderbilt Clinical Oncology Research Career Development Award (K12)
- AACR-Aflac, Inc. Scholar-in-Training Award
- Department of Defense Breast Cancer Research Program Postdoctoral Fellowship Award
- Department of Defense Breast Cancer Research Program Predoctoral Traineeship Award
- Highest Distinction, University of Virginia Distinguished Majors Project
- American Association for Cancer Research (2009)